Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 04 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.24 Insider Own51.30% Shs Outstand34.41M Perf Week-19.78%
Market Cap48.99M Forward P/E- EPS next Y-0.26 Insider Trans0.00% Shs Float10.70M Perf Month171.95%
Income-8.22M PEG- EPS next Q-0.17 Inst Own12.03% Short Float2.86% Perf Quarter284.55%
Sales42.63M P/S1.15 EPS this Y72.97% Inst Trans2.52% Short Ratio0.84 Perf Half Y175.31%
Book/sh0.69 P/B3.25 EPS next Y49.00% ROA-15.83% Short Interest0.31M Perf Year146.19%
Cash/sh2.11 P/C1.06 EPS next 5Y- ROE-31.45% 52W Range0.45 - 3.25 Perf YTD208.44%
Dividend Est.- P/FCF4.23 EPS past 5Y-70.20% ROI-33.41% 52W High-31.38% Beta1.64
Dividend TTM- Quick Ratio1.91 Sales past 5Y0.00% Gross Margin99.71% 52W Low395.56% ATR (14)0.34
Dividend Ex-Date- Current Ratio1.91 EPS Y/Y TTM89.88% Oper. Margin-21.77% RSI (14)56.91 Volatility14.01% 23.53%
Employees36 Debt/Eq0.04 Sales Y/Y TTM- Profit Margin-19.28% Recom1.00 Target Price6.50
Option/ShortYes / Yes LT Debt/Eq0.02 EPS Q/Q73.23% Payout- Rel Volume1.65 Prev Close2.50
Sales Surprise38.05% EPS Surprise38.89% Sales Q/Q- EarningsNov 08 AMC Avg Volume363.21K Price2.23
SMA2010.03% SMA5074.36% SMA200165.36% Trades Volume592,945 Change-10.80%
Date Action Analyst Rating Change Price Target Change
Oct-29-21Resumed Stifel Buy $12
Sep-15-21Initiated Cantor Fitzgerald Overweight $14
Jul-14-20Reiterated H.C. Wainwright Buy $14 → $24
Jul-10-20Resumed Stifel Buy $22 → $10
Feb-22-19Initiated SVB Leerink Outperform $16
Jan-29-24 04:07AM
Dec-21-23 09:52AM
Nov-20-23 11:23AM
Nov-13-23 09:00AM
04:01PM Loading…
Nov-08-23 04:01PM
Nov-06-23 08:00AM
Oct-24-23 12:30PM
Oct-19-23 08:00AM
Oct-16-23 08:00AM
Oct-03-23 08:00AM
Oct-02-23 08:00AM
Sep-20-23 08:00AM
Aug-30-23 08:00AM
Aug-12-23 08:05AM
05:30PM Loading…
Aug-09-23 05:30PM
Aug-02-23 04:00PM
Jun-01-23 08:00AM
May-15-23 08:00AM
May-11-23 05:25PM
May-03-23 06:14AM
Apr-24-23 08:00AM
Mar-23-23 04:01PM
Mar-22-23 08:00AM
Feb-17-23 08:00AM
Feb-07-23 08:00AM
Jan-13-23 08:00AM
Dec-23-22 04:01PM
08:00AM Loading…
Dec-16-22 08:00AM
Dec-06-22 12:17PM
Nov-14-22 04:01PM
Nov-10-22 08:00AM
Nov-08-22 08:00AM
Nov-03-22 08:00AM
Nov-02-22 08:00AM
Oct-26-22 08:00AM
Sep-27-22 08:15AM
Sep-15-22 08:00AM
Sep-07-22 05:58AM
Sep-06-22 04:00PM
Aug-31-22 08:00AM
Aug-18-22 07:48AM
Aug-15-22 04:01PM
Jul-28-22 08:00AM
Jun-14-22 02:09PM
May-17-22 08:00AM
May-12-22 04:01PM
May-09-22 08:00AM
Apr-25-22 08:00AM
Apr-04-22 08:00AM
Mar-29-22 10:00AM
Mar-28-22 12:00PM
Mar-24-22 08:00AM
Mar-23-22 04:01PM
Mar-04-22 08:00AM
Mar-01-22 08:00AM
Feb-16-22 11:22AM
Feb-15-22 08:00AM
Feb-09-22 08:00AM
Feb-02-22 06:46AM
Jan-10-22 08:00AM
Jan-05-22 08:00AM
Jan-04-22 12:48PM
Dec-13-21 08:00AM
Nov-09-21 08:00AM
Nov-05-21 08:00AM
Nov-04-21 09:00AM
Nov-02-21 11:23AM
Oct-18-21 08:00AM
Sep-30-21 08:00AM
Sep-22-21 08:00AM
Sep-08-21 08:00AM
Aug-11-21 04:00PM
Aug-10-21 04:01PM
Aug-06-21 04:42AM
Aug-05-21 08:00AM
Jul-13-21 09:10AM
Jul-12-21 04:01PM
Jun-11-21 09:53AM
Jun-10-21 08:00AM
Jun-09-21 08:00AM
Jun-07-21 08:00AM
Jun-03-21 08:00AM
May-26-21 08:00AM
May-17-21 08:00AM
May-13-21 04:02PM
Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March, 2017 and is headquartered in La Jolla, CA.